# Low magnesium on cetuximab and panitumumab: monitoring and replacement

Source: https://onco.cc/protocols/hypomagnesaemia-on-egfr-antibodies/  
OnCo record `hypomagnesaemia-on-egfr-antibodies` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Cetuximab and panitumumab make the kidneys lose magnesium, and the level tends to fall the longer treatment goes on. Blood magnesium, calcium and potassium are checked before, during and for about 8 weeks after treatment. Low levels are treated with magnesium tablets or a drip. Tell your team about cramp, tingling or numbness, palpitations or feeling faint. Your team's plan comes first.

## Summary

EGFR antibodies remove the signal that stimulates the magnesium channel TRPM6 in the distal convoluted tubule, so magnesium is lost in the urine; the fall worsens with duration of treatment and is reversible after the antibody stops. The US labels report decreased magnesium in 55% of patients on cetuximab (grade 3 or 4 in 6% to 17%) and 38% on panitumumab alone, 51% with FOLFOX and 69% with sotorasib. A pooled analysis of 25 randomised trials found all-grade hypomagnesaemia in 34.0% against 9.7% of controls, and more grade 3 or 4 hypokalaemia (6.7% against 3.7%). The cetuximab label carries a boxed warning for cardiopulmonary arrest in head and neck cancer and asks for magnesium, potassium and calcium monitoring during and after treatment. Grades are CTCAE version 5.0: grade 1 is below the laboratory's lower limit down to 0.5 mmol/L (1.2 mg/dL), grade 2 below 0.5 to 0.4 mmol/L (below 1.2 to 0.9 mg/dL), grade 3 below 0.4 to 0.3 mmol/L (below 0.9 to 0.7 mg/dL) and grade 4 below 0.3 mmol/L (below 0.7 mg/dL).

Monitoring is the only part the regulators specify, and they differ: the US cetuximab label says weekly during treatment and for at least 8 weeks after; the US and EU panitumumab texts say before, periodically during and for up to 8 weeks after; the EU cetuximab text says before and periodically during. No label sets a dose rule for low magnesium.

Replacement is not settled. One guideline addresses it: the Japanese 2022 guideline on kidney injury during anticancer drug therapy weakly recommends additional magnesium when hypomagnesaemia develops, rates the evidence D (very weak), and its recommendation names no dose or route. No ESMO, ASCO, MASCC or NCCN guideline was found. Published practice differs. One US centre (Fakih 2008) found oral magnesium ineffective and poorly tolerated and gave weekly intravenous magnesium sulfate 4 g for grade 2 at 0.9 to 1.0 mg/dL and about 6 to 10 g daily to twice weekly for grade 3 or 4. A nephrology review (Workeneh 2021) repeats this as 4 g weekly for grade 2 and 6 to 10 g daily for grade 3 or 4, and says parenteral magnesium should not exceed 1 g an hour unless there are seizures or a lethal arrhythmia. A Canadian review (Siddiqui 2021) supports early or preventive oral magnesium and keeps intravenous magnesium mainly for immediate correction, citing a randomised trial not read here. Where low potassium accompanies low magnesium it will not correct until the magnesium does, and severe hypomagnesaemia can cause low calcium. For refractory cases the options described are a planned break from the antibody (one centre's experience) and amiloride (suggested from its use in other causes of magnesium loss).

## Fields

- Kind: Protocol
- Last checked: 2026-11-17
- Also known as: cetuximab hypomagnesaemia; panitumumab hypomagnesaemia; EGFR antibody hypomagnesemia; magnesium wasting on anti-EGFR antibodies; low magnesium on Erbitux; low magnesium on Vectibix; electrolyte monitoring on cetuximab; magnesium replacement during cetuximab

## Connected records

- technologies: [Magnesium supplements](https://onco.cc/technologies/magnesium-supplements/)
- targets: [EGFR](https://onco.cc/targets/egfr/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Panitumumab](https://onco.cc/drugs/panitumumab/)
- terms: [QT prolongation](https://onco.cc/terms/qt-prolongation/)
- protocols: [Low potassium and low phosphate on anticancer drugs: monitoring, replacement and dose holds](https://onco.cc/protocols/low-potassium-and-low-phosphate-on-anticancer-drugs/), [QT prolongation on cancer medicines: ECG and blood salt monitoring, and when to pause or stop](https://onco.cc/protocols/qt-prolongation-monitoring-on-anticancer-drugs/)

---
JSON: https://onco.cc/api/v1/entities/hypomagnesaemia-on-egfr-antibodies.json